New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
10:49 EDTCERUCerulean 8.5M share IPO priced at $7
04/10/14--The deal size was raised to 8.5M from 5M shares and priced below the $11-$13 range. Leerink acted as lead book running manager for the offering.
News For CERU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
08:30 EDTCERUCerulean announces first patient dosed with CRLX301 in Phase 1/2a trial
Cerulean Pharma announced that the first patient has been dosed with CRLX301 in Cerulean’s Phase 1/2a trial in patients with advanced solid tumor malignancies. CRLX301 is a nanoparticle-drug conjugate, or NDC, with a docetaxel payload, and it is the second clinical candidate from Cerulean’s Dynamic Tumor Targeting Platform.“CRLX301 was superior to docetaxel in seven of seven animal models, with a statistically significant survival benefit in five of those preclinical models,” said Paul Friedman, M.D., Executive Chairman of Cerulean. “We also saw preclinical tolerability that is consistent with our expectations of the platform -- specifically, improved tolerability relative to published data with docetaxel. We look forward to learning if these preclinical results will translate in the clinic.” This is the first clinical trial of CRLX301. The Phase 1/2a trial is commencing in Australia and is expected to expand to the U.S. The Phase 1 portion is a single-arm, open-label, dose-escalation study of CRLX301 in up to 36 patients with advanced solid tumor malignancies that is designed to identify the maximum tolerated dose and establish the recommended Phase 2 dose of CRLX301 when administered by intravenous infusion once every three weeks. The Phase 2a portion will be an expansion cohort that will enroll an additional 24 patients. The primary endpoints are pharmacokinetics, safety and tolerability of CRLX301. Preliminary evidence of efficacy also will be evaluated.
December 15, 2014
09:04 EDTCERUCerulean completes enrollment in Phase 1b/2 study of CRLX101, Avastin
Cerulean Pharma announced completion of enrollment of 22 patients in a Phase 1b/2 clinical proof of principle trial of its lead nanoparticle-drug conjugate, CRLX101, in combination with Avastin in relapsed renal cell carcinoma. This study is an investigator-sponsored trial being conducted by the University of Pennsylvania and Thomas Jefferson University Hospital with support from Cerulean. The Principal Investigator is Dr. Stephen Keefe of the University of Pennsylvania Abramson Cancer Center. Data previously presented from the first 11 patients from this study showed a 27% response rate in a setting where standard of care historically provides only a 2-4% response rate. A 7.6 months median progression-free survival was observed, which is double the roughly 3.5 months PFS achieved by standard-of-care in this setting. Based on these data, Cerulean launched a company-sponsored randomized Phase 2 trial of CRLX101 in combination with Avastin in 3rd and 4th line RCC in August 2014, which is currently ongoing.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use